IMMUNOPRECISE ANTIBODIES LTD (IPA) Stock Price, Forecast & Analysis
USA - NASDAQ:IPA - CA45257F2008 - Common Stock
IPA Key Statistics, Chart & Performance
The current stock price of IPA is 2.07 USD. In the past month the price increased by 14.36%. In the past year, price increased by 209.19%.
IPA Latest News, Press Relases and Analysis
IPA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.34 | 214.35B | ||
| DHR | DANAHER CORP | 27.52 | 151.95B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 160.81 | 48.80B | ||
| A | AGILENT TECHNOLOGIES INC | 26.93 | 41.61B | ||
| IQV | IQVIA HOLDINGS INC | 18.07 | 35.72B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.2 | 29.66B | ||
| WAT | WATERS CORP | 29.29 | 22.14B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 40.1 | 20.39B | ||
| ILMN | ILLUMINA INC | 28.08 | 18.82B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.87 | 16.82B | ||
| TEM | TEMPUS AI INC | N/A | 14.29B | ||
| ICLR | ICON PLC | 12.41 | 12.73B |
Related stock screener links
About IPA
Company Profile
ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The company is headquartered in Austin, Texas. The company is advancing Bio-Native AI at the intersection of biology and computation. Its LENSai and HYFT platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. The core of its operations encompasses a diverse suite of proprietary technologies that aid in the exploration, discovery, and development of novel drugs and biologics. Integrated within its wet lab infrastructure is a diverse array of in silico technologies. As an end-to-end service provider of antibody discovery and development, its computational methodologies allow the Company to perform detailed and comprehensive evaluations across various stages of biologic discovery and development. The company is involved in antibody characterization studies, which encompass affinity measurements, epitope landscape profiling, and others.
Company Info
IMMUNOPRECISE ANTIBODIES LTD
Industrious 823 Congress Ave Suite 300
Austin TEXAS US
Employees: 102
Phone: 16048060626
IMMUNOPRECISE ANTIBODIES LTD / IPA FAQ
What does IMMUNOPRECISE ANTIBODIES LTD do?
ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The company is headquartered in Austin, Texas. The company is advancing Bio-Native AI at the intersection of biology and computation. Its LENSai and HYFT platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. The core of its operations encompasses a diverse suite of proprietary technologies that aid in the exploration, discovery, and development of novel drugs and biologics. Integrated within its wet lab infrastructure is a diverse array of in silico technologies. As an end-to-end service provider of antibody discovery and development, its computational methodologies allow the Company to perform detailed and comprehensive evaluations across various stages of biologic discovery and development. The company is involved in antibody characterization studies, which encompass affinity measurements, epitope landscape profiling, and others.
Can you provide the latest stock price for IMMUNOPRECISE ANTIBODIES LTD?
The current stock price of IPA is 2.07 USD. The price increased by 7.25% in the last trading session.
Does IPA stock pay dividends?
IPA does not pay a dividend.
What is the ChartMill rating of IMMUNOPRECISE ANTIBODIES LTD stock?
IPA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for IPA stock?
IMMUNOPRECISE ANTIBODIES LTD (IPA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).
Is IMMUNOPRECISE ANTIBODIES LTD (IPA) expected to grow?
The Revenue of IMMUNOPRECISE ANTIBODIES LTD (IPA) is expected to grow by 13.46% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of IPA stock?
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a market capitalization of 95.53M USD. This makes IPA a Micro Cap stock.
IPA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IPA. When comparing the yearly performance of all stocks, IPA is one of the better performing stocks in the market, outperforming 98.62% of all stocks.
IPA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IPA. Both the profitability and financial health of IPA have multiple concerns.
IPA Financial Highlights
Over the last trailing twelve months IPA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 34.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.03% | ||
| ROE | -127.97% | ||
| Debt/Equity | 0.49 |
IPA Forecast & Estimates
6 analysts have analysed IPA and the average price target is 5.1 USD. This implies a price increase of 146.38% is expected in the next year compared to the current price of 2.07.
For the next year, analysts expect an EPS growth of 49.5% and a revenue growth 13.46% for IPA